The independent medical news service

Click through to find out more

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

More details about this decision available here

Ultra-hypofractionated stereotactic body radiotherapy has a low rate of side effects, similar to a standard course of conventionally or moderately hypofractionated radiotherapy for low- or intermediate-risk prostate cancer, indicate 2-year toxicity findings from the phase 3 PACE-B trial.

Long-term postoperative androgen deprivation therapy may improve metastasis-free survival versus short-term therapy in men receiving radiotherapy after radical prostatectomy for prostate cancer, research suggests.

Rezvilutamide significantly delays disease progression and death relative to bicalutamide when each is combined with androgen deprivation therapy in patients with high-volume metastatic, hormone-sensitive prostate cancer, research shows.